tea4 Antibody

What is TEAD4 and why is it important in cellular research?

TEAD4 is a member of the transcriptional enhancer factor (TEF) family of transcription factors containing the TEA/ATTS DNA-binding domain. It plays a critical role as a key component of the Hippo signaling pathway, regulating gene expression and influencing cell fate decisions . TEAD4 is preferentially expressed in skeletal muscle tissue and binds to the M-CAT regulatory element found in promoters of muscle-specific genes to direct their expression .

The significance of TEAD4 in cellular research stems from its established role in controlling organ size and tumorigenesis, making it a compelling target for cancer research and regenerative medicine studies . By using TEAD4 antibodies, researchers can detect, analyze, and quantify TEAD4 expression patterns across different cell types, providing valuable insights into its functional mechanisms and potential therapeutic applications.

What types of TEAD4 antibodies are available for research applications?

Several types of TEAD4 antibodies are available for research purposes, each optimized for specific applications:

• Monoclonal antibodies: These offer high specificity and consistency between batches, such as the TEAD4 Monoclonal Antibody (CAB23774) generated in rabbit hosts .

• Polyclonal antibodies: These recognize multiple epitopes of TEAD4, potentially offering higher sensitivity but with batch-to-batch variation.

• Conjugated antibodies: Some TEAD4 antibodies may be available with fluorescent or enzymatic conjugates for direct detection in specific applications.

• Recombinant antibodies: Produced through in vitro methods rather than animal immunization.

The selection criteria should be based on the intended application, with considerations for host species, epitope location, and validation data in specific experimental contexts.

How do I select the appropriate TEAD4 antibody for my specific research needs?

When selecting a TEAD4 antibody, consider these critical factors:

• Application compatibility: Ensure the antibody has been validated for your intended application (e.g., Western blot, ELISA, immunohistochemistry) .

• Host species: Consider potential cross-reactivity issues. For example, if your samples contain rabbit proteins and you plan to use other rabbit antibodies, a TEAD4 antibody raised in a different species would be preferable.

• Epitope location: Verify whether the antibody recognizes an epitope within your region of interest. For instance, the CAB23774 antibody targets a synthetic peptide corresponding to a sequence within amino acids 140-240 of human TEAD4 .

• Species reactivity: Confirm the antibody reacts with TEAD4 from your study species. Some TEAD4 antibodies are specifically reactive with human samples .

• Validation data: Review documentation of antibody specificity, including positive control samples (e.g., HepG2 and HeLa cell lines for CAB23774) .

What are the standard storage and handling procedures for TEAD4 antibodies?

Proper storage and handling are essential for maintaining antibody performance:

• Storage temperature: Most TEAD4 antibodies should be stored at -20°C for long-term storage or at 4°C for short periods after reconstitution.

• Freeze-thaw cycles: Minimize freeze-thaw cycles to prevent antibody degradation. Aliquot the antibody upon first thaw if multiple uses are planned.

• Reconstitution: Use appropriate buffers as recommended by the manufacturer.

• Working dilutions: Prepare fresh working dilutions on the day of the experiment. For example, Western blot applications typically use dilutions of 1:500 to 1:1000 for TEAD4 monoclonal antibodies .

• Contamination prevention: Use sterile techniques when handling antibodies to prevent microbial contamination.

• Documentation: Maintain detailed records of antibody lot numbers, dilutions, and experimental conditions to ensure reproducibility.

What are the optimal protocols for using TEAD4 antibodies in Western Blot experiments?

A standardized Western Blot protocol for TEAD4 detection includes:

• Sample preparation:

  • Lyse cells in RIPA buffer supplemented with protease inhibitors

  • Quantify protein concentration using BCA or Bradford assay

  • Denature samples at 95°C for 5 minutes in Laemmli buffer

• Gel electrophoresis:

  • Load 20-40 μg of protein per lane

  • Use 10-12% SDS-PAGE gels for optimal resolution around 58 kDa (observed molecular weight of TEAD4)

• Transfer and blocking:

  • Transfer proteins to PVDF or nitrocellulose membrane

  • Block with 5% non-fat dry milk or BSA in TBST for 1 hour at room temperature

• Antibody incubation:

  • Dilute primary TEAD4 antibody 1:500 to 1:1000 in blocking solution

  • Incubate overnight at 4°C with gentle rocking

  • Wash 3-5 times with TBST

  • Incubate with appropriate HRP-conjugated secondary antibody for 1 hour at room temperature

  • Wash thoroughly with TBST

• Detection:

  • Apply ECL substrate and image using a digital imaging system

  • Expected band size is approximately 58 kDa for TEAD4

• Controls:

  • Include HepG2 or HeLa cell lysates as positive controls

  • Include a loading control (e.g., β-actin, GAPDH)

How should I optimize immunohistochemistry protocols for TEAD4 detection?

For successful immunohistochemistry (IHC) with TEAD4 antibodies:

• Tissue preparation:

  • Fix tissues in 10% neutral buffered formalin

  • Embed in paraffin and section at 4-6 μm thickness

  • For frozen sections, fix briefly in cold acetone or 4% paraformaldehyde

• Antigen retrieval:

  • Perform heat-induced epitope retrieval in citrate buffer (pH 6.0) or EDTA buffer (pH 9.0)

  • Heat in a pressure cooker or microwave until boiling, then maintain for 15-20 minutes

  • Cool to room temperature gradually

• Blocking and antibody incubation:

  • Block endogenous peroxidase with 3% H2O2

  • Block non-specific binding with 5-10% normal serum from the same species as the secondary antibody

  • Apply primary TEAD4 antibody at optimized dilution

  • Incubate overnight at 4°C in a humidified chamber

• Detection system:

  • Use an appropriate detection system (e.g., HRP-polymer, ABC kit)

  • Develop with DAB substrate and counterstain with hematoxylin

  • Mount with permanent mounting medium

• Controls and interpretation:

  • Include positive controls (tissues known to express TEAD4)

  • Include negative controls (primary antibody omission)

  • Expect nuclear localization of TEAD4 staining

What validation methods should I employ to confirm TEAD4 antibody specificity?

Thorough validation is essential to ensure experimental results are reliable:

• Western blot analysis:

  • Verify single band at expected molecular weight (58 kDa for TEAD4)

  • Compare observed band pattern with predicted molecular weights (34kDa/44kDa/48kDa calculated) and account for potential post-translational modifications

• Positive and negative controls:

  • Use cell lines known to express TEAD4 (e.g., HepG2, HeLa)

  • Include TEAD4 knockout or knockdown samples as negative controls

• Peptide competition assay:

  • Pre-incubate the antibody with excess immunizing peptide

  • Compare results with and without peptide competition

• Orthogonal validation:

  • Confirm results using multiple antibodies targeting different epitopes

  • Correlate protein detection with mRNA expression data

• Cross-reactivity assessment:

  • Test the antibody against recombinant proteins of related TEAD family members

  • Evaluate specificity across multiple species if relevant to your research

What quality control metrics should be considered when evaluating commercially available TEAD4 antibodies?

When evaluating TEAD4 antibodies, consider these quality metrics:

Quality commercial TEAD4 antibodies should provide detailed documentation of these metrics, including sequence information, recommended dilutions, and positive control samples .

How can TEAD4 antibodies be utilized in studying the Hippo signaling pathway?

TEAD4 antibodies enable sophisticated analyses of the Hippo pathway:

• Co-immunoprecipitation (Co-IP):

  • Investigate TEAD4 interactions with YAP/TAZ cofactors and other binding partners

  • Characterize the composition of transcriptional complexes in different cellular contexts

• Chromatin immunoprecipitation (ChIP):

  • Map TEAD4 binding sites across the genome

  • Analyze how TEAD4 occupancy changes in response to Hippo pathway activation/inhibition

  • Investigate cooperation with other transcription factors at target gene promoters

• Proximity ligation assays (PLA):

  • Visualize and quantify TEAD4-YAP/TAZ interactions in situ

  • Analyze spatial distribution of interactions within subcellular compartments

• Immunofluorescence co-localization:

  • Examine nuclear localization patterns of TEAD4 and YAP/TAZ

  • Correlate with cellular phenotypes and Hippo pathway activation status

• Phosphorylation-specific analyses:

  • Use phospho-specific antibodies in conjunction with TEAD4 antibodies

  • Investigate how post-translational modifications affect TEAD4 function

What techniques incorporating TEAD4 antibodies are useful in cancer research?

TEAD4 antibodies enable several specialized techniques in cancer research:

• Tumor tissue microarray (TMA) analysis:

  • Profile TEAD4 expression across multiple tumor samples simultaneously

  • Correlate expression with clinicopathological features and patient outcomes

• Patient-derived xenograft (PDX) studies:

  • Monitor TEAD4 expression in tumor models treated with Hippo pathway modulators

  • Assess correlation between TEAD4 activity and therapeutic response

• Cell-based high-content screening:

  • Develop immunofluorescence-based assays to screen for compounds affecting TEAD4 activity

  • Quantify nuclear-cytoplasmic distribution in response to drug treatments

• Circulating tumor cell (CTC) analysis:

  • Detect TEAD4 expression in CTCs as a potential biomarker

  • Correlate with disease progression or metastatic potential

• Drug resistance mechanisms:

  • Investigate TEAD4 expression changes in drug-resistant cancer cell populations

  • Identify TEAD4-dependent resistance pathways that could be therapeutically targeted

How do computational approaches enhance TEAD4 antibody design and application?

Recent advances in computational methods are transforming antibody design:

• Deep learning-based sequence generation:

  • Algorithms can now generate novel antibody variable regions with desirable properties

  • These computational approaches can potentially be applied to create TEAD4-specific antibodies with optimized developability attributes

• In-silico antibody screening:

  • Virtual screening of antibody libraries against TEAD4 structural models

  • Prediction of binding affinity and specificity before experimental validation

• Epitope mapping and optimization:

  • Computational prediction of immunogenic epitopes within TEAD4

  • Design of antibodies targeting conserved or functionally important regions

• Developability assessment:

  • Algorithms can predict properties like expression levels, stability, and non-specific binding

  • Experimental validation shows that in-silico generated antibodies can exhibit high expression, monomer content, and thermal stability

Computational methods offer several advantages, including:

• Reduced reliance on animal immunization

• Faster generation of candidate antibodies

• Optimization for specific applications

• Potential to target epitopes that are challenging via conventional methods

How can single-cell analysis technologies be combined with TEAD4 antibodies?

Integration of TEAD4 antibodies with single-cell technologies enables:

• Single-cell proteomics:

  • Mass cytometry (CyTOF) incorporating TEAD4 antibodies for high-dimensional protein profiling

  • Correlation of TEAD4 expression with dozens of other proteins at single-cell resolution

• Spatial transcriptomics with protein detection:

  • Combined analysis of TEAD4 protein localization and gene expression patterns

  • Mapping of spatial relationships between TEAD4-expressing cells and their microenvironment

• Multiparameter flow cytometry:

  • Multi-color panels including TEAD4 antibodies for complex phenotyping

  • Sorting of cell populations based on TEAD4 expression for downstream analysis

• Live-cell imaging with tagged antibody fragments:

  • Dynamic visualization of TEAD4 localization in living cells

  • Real-time monitoring of responses to experimental manipulations

• Single-cell western blotting:

  • Quantification of TEAD4 protein levels in individual cells

  • Correlation with other proteins in the Hippo pathway

What are common technical challenges when using TEAD4 antibodies and how can they be resolved?

Systematic optimization and thorough controls are essential for overcoming these challenges.

How should researchers interpret contradictory results from different TEAD4 antibodies?

When faced with contradictory results:

• Compare epitope locations:

  • Different epitopes may be differentially accessible or affected by post-translational modifications

  • Map the epitopes to the TEAD4 protein structure and consider functional domains

• Evaluate validation rigor:

  • Assess the validation evidence for each antibody

  • Consider specificity data, knockout controls, and publication record

• Consider isoform specificity:

  • TEAD4 has multiple isoforms (observed MW of 58kDa vs. calculated MWs of 34kDa/44kDa/48kDa)

  • Determine which isoforms each antibody recognizes

• Orthogonal validation:

  • Confirm results with non-antibody methods (e.g., RNA-seq, mass spectrometry)

  • Use genetic approaches (siRNA, CRISPR) to validate specificity

• Reconciliation strategies:

  • Design experiments to directly compare antibodies under identical conditions

  • Consider context-dependent factors (cell type, fixation, protein conformation)

  • Consult literature for similar discrepancies and resolution approaches

What statistical approaches are recommended for analyzing TEAD4 expression data?

• Expression level quantification:

  • Normalize Western blot data to loading controls

  • Use densitometry software with appropriate background subtraction

  • For IHC, consider H-score, Allred score, or digital image analysis

• Sample size determination:

  • Perform power analysis based on expected effect sizes

  • Account for biological and technical variability

• Appropriate statistical tests:

  • For comparing two groups: t-test or non-parametric alternatives

  • For multiple groups: ANOVA with appropriate post-hoc tests

  • For correlations with clinical outcomes: survival analysis (Kaplan-Meier, Cox regression)

• Multiple testing correction:

  • Apply FDR or Bonferroni correction when conducting multiple comparisons

  • Be cautious of data dredging and post-hoc hypotheses

• Reproducibility considerations:

  • Report technical and biological replicates separately

  • Pre-register analysis plans when possible

  • Share raw data and analysis code

How might deep learning approaches transform TEAD4 antibody development?

Deep learning is revolutionizing antibody development with potential applications for TEAD4 antibodies:

• Generative models for antibody design:

  • Deep learning algorithms like WGAN+GP can generate novel antibody sequences with desired properties

  • These in-silico generated antibodies have demonstrated high expression, monomer content, and thermal stability comparable to marketed antibodies

• Performance prediction:

  • AI models can predict biophysical properties (stability, solubility, aggregation) before experimental production

  • This allows pre-screening of candidates, saving time and resources

• Epitope-specific optimization:

  • Machine learning can optimize antibody sequences for specific TEAD4 epitopes

  • This might allow targeting of previously challenging regions

• Developability profile enhancement:

  • AI can generate antibodies with "medicine-like" properties resembling successful biotherapeutics

  • Experimental validation has shown that computationally designed antibodies compare favorably with clinical-stage antibodies in key biophysical attributes

These data demonstrate that computationally designed antibodies can match or exceed the performance of conventionally developed antibodies .

What are emerging applications of TEAD4 antibodies in therapeutic development?

While primarily research tools, TEAD4 antibodies are finding emerging therapeutic applications:

• Target validation:

  • Confirming TEAD4's role in disease models before small molecule inhibitor development

  • Identifying patient populations likely to respond to TEAD4-targeting therapies

• Companion diagnostics:

  • Development of IHC-based assays to stratify patients for clinical trials

  • Monitoring TEAD4 expression as a biomarker of treatment response

• Antibody-drug conjugates (ADCs):

  • Potential development of ADCs targeting TEAD4 in cancers with membrane-associated or extracellular TEAD4

  • Delivery of cytotoxic payloads to TEAD4-expressing tumor cells

• Intrabodies:

  • Engineering antibody fragments for intracellular delivery to directly inhibit TEAD4 function

  • Disruption of TEAD4-YAP/TAZ interactions in cancer cells

• Bispecific antibodies:

  • Creating antibodies that simultaneously target TEAD4 and other components of the Hippo pathway

  • Enhancing specificity for particular tumor types or signaling contexts

How can researchers optimize TEAD4 antibodies for multiplexed imaging applications?

Advanced multiplexed imaging requires specialized antibody preparation:

• Antibody conjugation strategies:

  • Direct fluorophore conjugation with minimal impact on binding properties

  • Site-specific conjugation to avoid interference with antigen recognition

  • Optimization of fluorophore-to-antibody ratio for signal intensity

• Sequential staining protocols:

  • Development of antibody stripping/quenching methods for sequential rounds of staining

  • Validation of epitope preservation across multiple staining cycles

• Spectral unmixing considerations:

  • Selection of fluorophores with minimal spectral overlap

  • Calibration standards for accurate signal separation in highly multiplexed experiments

• Antibody panels:

  • Design of compatible antibody panels including TEAD4 and related proteins

  • Optimization of antibody combinations to minimize cross-reactivity

• Spatial analysis integration:

  • Development of computational pipelines for spatial relationship analysis

  • Correlation of TEAD4 expression with tissue architecture and microenvironment features

What quality control advancements are improving TEAD4 antibody reliability?

Emerging quality control strategies include:

• Standardized validation initiatives:

  • Implementation of community-wide validation standards

  • Open sharing of validation data across laboratories

• Recombinant antibody technologies:

  • Shifting from hybridoma-produced to recombinant antibodies for improved batch consistency

  • Sequence-defined antibodies eliminating hybridoma drift issues

• Application-specific validation:

  • Customized validation workflows for specific experimental contexts

  • Expanded panels of positive and negative controls

• Automated quality assessment:

  • High-throughput screening of antibody performance metrics

  • Machine learning algorithms for predicting antibody performance in specific applications

• Reference standards:

  • Development of standard reference materials for TEAD4 quantification

  • Calibration tools for cross-laboratory standardization